GSBR-1290

Schrödinger expands collaboration with Otsuka Pharmaceutical and anticipates $150 million upfront payment from Novartis in Q1 2025.

Viking Therapeutics has commenced a Phase 2 clinical trial for oral VK2735, a dual GLP-1/GIP agonist, to treat obesity.

Structure Therapeutics, Inc. has been awarded a Buy rating by Stifel Nicolaus analyst Annabel Samimy, thanks to its innovative oral small molecule treatments for obesity. The company's lead candidate, GSBR-1290, has shown promising early trial results, indicating potential for widespread use in primary care settings. Despite challenges, the company's strategic approach and diversified pipeline support the positive outlook.

JPMorgan highlights Viking Therapeutics and Structure Therapeutics as attractive options for pharmaceutical companies aiming to enter the T2D/obesity market, citing their potential for strategic partnerships and clinical trial data.

UNITY Biotechnology appointed Federico Grossi as Chief Medical Officer, enhancing its leadership with his extensive experience in ophthalmology and drug development.